Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NQO2 | P16083 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | PLAT | P00750 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2148501 | 0.98 | TSHR (0.64) | TSHRNQO2LMNAGAAPRSS1 | |
| Guanidine SCHEMBL27922792 | 0.86 | TSHR (0.64) | TSHRLMNAGAAPRSS1PRSS2 | |
| SCHEMBL21665459 | 0.82 | PRMT1 (0.71) | PRSS1F10PLAU | |
| SCHEMBL14599534 | 0.81 | F2 (0.71) | PRSS1PRSS2PRSS3CA1CA2 | |
| SCHEMBL260727 | 0.80 | TSHR (1.00) | TSHRLMNAGAACES1CA1 | |
| Terephthalamide SCHEMBL27950892 | 0.80 | TSHR (1.00) | TSHRLMNAGAACES1CA1 | |
| Urea SCHEMBL27805729 | 0.79 | TSHR (0.74) | TSHRLMNAGAACES1CA1 | |
| SCHEMBL10994348 | 0.78 | ALDH1A1 (0.67) | TSHRLMNAGAACES1CA1 | |
| SCHEMBL16089346 | 0.78 | MAPK1 (0.67) | TSHRNQO2LMNACES1CA1 | |
| SCHEMBL874833 | 0.78 | TSHR (0.67) | TSHRLMNAGAACES1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119674190-A | Organic-inorganic composite polymer solid electrolyte and preparation method and application thereof | 山东创鲁先进电池科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-116162064-A | Synthesis method of dabigatran etexilate special intermediate | 宿迁盛基医药科技有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-105330568-B | Preparation method for p-aminobenzamidine hydrochloride | 山东省医学科学院药物研究所 | 2017-05-10 | — | — | CN | claimed |
| CN-105330568-A | Preparation method for p-aminobenzamidine hydrochloride | INST OF MATERIA MEDICA SHANDONG ACADEMY OF MEDICAL SCIENCES | 2016-02-17 | — | — | CN | claimed |
| US-20230219896-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219896-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230202983-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230202983-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-06-29 | — | — | US | disclosed |
| CN-116162064-A | Synthesis method of dabigatran etexilate special intermediate | 宿迁盛基医药科技有限公司 | 2023-05-26 | — | — | CN | disclosed |
| EP-4147700-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE | LQT Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | disclosed |
| US-11155521-B2 | Cannabinoid receptor mediating compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-10-26 | — | — | US | disclosed |
| EP-2919779-B1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | US HEALTH (US) | 2021-01-06 | — | — | EP | disclosed |
| US-4259482-A | NON-SPECIFIC DEPRESSION OF CENTRAL NERVOUS SYSTEM | MEAD JOHNSON & COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4206142-A | REACTING A STYRYLSULFONYLAMIDINE WITH A BASE | MEAD JOHNSON & COMPANY (US) | 1980-06-03 | — | — | US | disclosed |
| US-4130663-A | ANTITHROMBOGENIC, ANTIHYPERTENSIVE | MEAD JOHNSON & COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
| US-4096183-A | Styrylsulfonylamidines | MEAD JOHNSON & COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4052455-A | ANALGESICS, BLOOD PLATELET AGGREGATION INHIBITORS | MEAD JOHNSON & COMPANY (US) | 1977-10-04 | — | — | US | disclosed |
| US-4018814-A | ANTHELMINTICS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-04-19 | — | — | US | disclosed |
| US-4013676-A | NEMATOCIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-22 | — | — | US | disclosed |
| US-3996247-A | ANTHELMINTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219896-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | TSHR 606/4885NQO2 4269/4885LMNA 4242/4885 |
| US-20230202983-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | TSHR 606/4885NQO2 4269/4885LMNA 4242/4885 |
| US-11155521-B2 | Cannabinoid receptor mediating compounds | CNR1, CNR2, GPR18 | TSHR 611/4885NQO2 4511/4885LMNA 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.